US Bancorp DE Purchases 135 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

US Bancorp DE grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,235 shares of the company’s stock after acquiring an additional 135 shares during the quarter. US Bancorp DE’s holdings in Medpace were worth $2,736,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in MEDP. R Squared Ltd bought a new stake in Medpace in the 4th quarter worth approximately $30,000. Stone House Investment Management LLC bought a new stake in Medpace in the 3rd quarter worth approximately $33,000. Ashton Thomas Securities LLC bought a new stake in Medpace in the 3rd quarter worth approximately $37,000. Capital Performance Advisors LLP bought a new stake in Medpace in the 3rd quarter worth approximately $46,000. Finally, True Wealth Design LLC boosted its holdings in shares of Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after purchasing an additional 168 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 0.9 %

MEDP opened at $325.73 on Friday. The business has a fifty day moving average of $341.27 and a 200 day moving average of $344.03. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The stock has a market cap of $9.92 billion, a P/E ratio of 25.79, a PEG ratio of 3.81 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird lifted their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.